SWEDEN - SLS Invest backs Gyros with SEK 80m

Gyros provides automated micro-immunoassays for therapeutic protein development. The Gyros systems are used by among others Pfizer, Amgen, Ablynx and Merck. Founded in 2000 as a spin-off from Amersham Biosciences, it currently employs 50 people in its headquarters in Uppsala, and in regional sales offices in the US and the UK.

The recent capital increase will finance continued commercialisation of the products.

The business has previously received financing from among others AP Funds, Investor Growth Capital HealthCap Private Equity, SV Life Sciences and 3i.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Nordics